Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Zimmer Holdings, Inc. : Zimmer Receives FDA Warning on Certain Hip Implants

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/02/2012 | 12:40am CET

--Zimmer says FDA inspection of Puerto Rico plant turned up concerns about manufacturing of certain implants

--FDA in letter noted manufacturing, testing issues related to Trilogy Acetabuar System products, company says

--Zimmer says it is notifying customers of manufacturing issue, but hasn't withdrawn any products

(Adds context on metallic spikes in fourth paragraph and a no comment from Zimmer in seventh paragraph.)

 
   By Kristin Jones 
 

Zimmer Holdings Inc. (ZMH) said a U.S. Food and Drug Administration inspection of its plant in Puerto Rico turned up concerns about the manufacturing of certain hip implants.

The orthopedic maker's Zimmer Inc. subsidiary received a warning letter from the FDA dated Sept. 19, the company said in a regulatory filing Monday. In the letter, the FDA noted manufacturing and testing issues related to the company's Trilogy Acetabular System products, which are implanted in hip-replacement surgery.

Specifically, the U.S. drug regulator noted that Zimmer hadn't implemented a testing mechanism to show that its products met design specifications. The company also hadn't validated the effect of certain manufacturing operations on Trilogy products that incorporate metallic spikes.

Spikes are used to connect the hip replacement cup to a patient's bone when cement and screws are deemed insufficient.

The FDA requires that drug and medical-device makers undertake steps to ensure the quality of the design and manufacture of its products, known as process validation.

Zimmer said it is notifying customers of the manufacturing issue, but that it hasn't withdrawn any products. The company also said it previously suspended release of the spiked products, pending validation of the processes cited in the letter, and expects to complete validation in the next few weeks.

A Zimmer spokesman declined to comment further.

Shares gained 11 cents to $67.98 in after-hours trading. Through Monday's close, the stock was up 27% so far this year.

--Joseph Walker contributed to this article.

Write to Kristin Jones at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
11/21 ZIMMER BIOMET : to Present at 29th Annual Piper Jaffray Healthcare Conference
11/08 ZIMMER BIOMET : to Present at Jefferies 2017 London Healthcare Conference
11/06 ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
11/03 ZIMMER BIOMET : Reports Third Quarter 2017 Financial Results
11/01 ZIMMER BIOMET : misses Street 3Q forecasts
11/01 ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
11/01 ZIMMER BIOMET : Reports Third Quarter 2017 Financial Results
10/27ZIMMER BIOMET HOLDINGS INC : quaterly earnings release
10/27 ZIMMER BIOMET HOLDINGS INC : Corporate News Blog - Zimmer Biomet Launches Vitali..
10/27 ZIMMER BIOMET : Announces U.S. Launch of Vitality+ and Vital Spinal Fixation Sys..
More news
News from SeekingAlpha
11/21 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
11/14 Premarket analyst action - healthcare
11/08 GENERAL ELECTRIC : Speculation Runs Rampant Ahead Of Investor Update
11/02 Premarket analyst action - healthcare
11/01 Zimmer Biomet's (ZBH) CEO Dan Florin on Q3 Results - Earnings Call Transcript
Financials ($)
Sales 2017 7 776 M
EBIT 2017 2 436 M
Net income 2017 869 M
Debt 2017 9 437 M
Yield 2017 0,85%
P/E ratio 2017 25,49
P/E ratio 2018 20,11
EV / Sales 2017 4,17x
EV / Sales 2018 3,95x
Capitalization 22 993 M
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Technical analysis trends ZIMMER BIOMET HOLDINGS INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 131 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Daniel P. Florin Director, Chief Executive & Financial Officer
Larry C. Glasscock Non-Executive Chairman
Adrian Furey Senior VP-Global Operations & Logistics
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Arthur Joseph Higgins Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS INC8.15%22 993
MEDTRONIC PLC11.60%106 877
BAXTER INTERNATIONAL44.07%34 804
C R BARD INC48.47%24 294
ALIGN TECHNOLOGY164.11%20 486
HOYA CORPORATION18.17%20 102